Gene test could match prostate cancer patients to better chemo
NCT ID NCT02955082
First seen Feb 04, 2026 · Last updated May 01, 2026 · Updated 13 times
Summary
This study looks at whether men with advanced prostate cancer that no longer responds to hormone therapy have certain gene changes that make them respond better to the chemotherapy drug carboplatin. Researchers will first test participants for these gene changes, and those with the changes will receive carboplatin to see if their tumors shrink or PSA levels drop. The goal is to use genetic profiles to personalize prostate cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE REFRACTORY PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Cancer Research and Royal Marsden Hospital
Sutton, Surrey, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.